List view / Grid view
4 October 2013 | By GlaxoSmithKline
GlaxoSmithKline plc and Genmab announced the submission of a variation to the Marketing Authorisation to the European Medicines Agency (EMA) for the use of Arzerra...
4 October 2013 | By Amgen
Prolia open-label extension trial showed continued increases in bone mineral density and low fracture incidence for up to eight years...
4 October 2013 | By Biogen Idec
Interim results from ENDORSE extension study reinforce favorable safety profile in patients treated for up to six and a half years...
3 October 2013 | By Sanofi
Data presented at ECTRIMS highlight potential of early intervention with Aubagio to delay second clinical attack and reduce MRI lesion burden...
3 October 2013 | By Biogen Idec
“These analyses build upon a growing body of evidence that demonstrates greater clinical benefits for people with MS when TYSABRI is initiated earlier in the course of the disease..."
3 October 2013 | By Amgen
"The Phase 2 data demonstrate that the primary and secondary end points were met..."
3 October 2013 | By Pfizer Inc.
“The approval of DUAVEE, an important, novel and effective treatment, presents a new opportunity for women..."
3 October 2013 | By Celgene
Psoriasis of the scalp, another difficult-to-treat area, was also improved by treatment with apremilast 30 mg BID...
AbbVie (NYSE: ABBV) today announced results from a post-hoc analysis of an investigational Phase II study, which evaluated HUMIRA® (adalimumab) in the treatment of patients with moderate-to-severe hidradenitis suppurativa (HS) after 16 weeks of therapy.1
3 October 2013 | By Johnson & Johnson
Collaborations announced between regional innovators and Johnson & Johnson family of companies...
3 October 2013 | By Teva Pharmaceutical Industries Ltd
Teva believes unpredictable differences between a proposed generic product and COPAXONE® could lead to immunogenic effects in patients...
3 October 2013 | By Teva Pharmaceutical Industries Ltd
“To our knowledge, glatiramer acetate is the only treatment for multiple sclerosis that has been prospectively studied for nearly two decades..."
3 October 2013 | By Novartis
"Controlling relapses and preventing disability are key treatment goals for patients with MS..."
2 October 2013 | By AstraZeneca
AstraZeneca announced that the US Court of Appeals for the Federal Circuit (CAFC) lifted a temporary injunction against the US launch of Hanmi's 505(b)2 NDA esomeprazole strontium product...
2 October 2013 | By AstraZeneca
Hanmi’s launch would be at risk of owing AstraZeneca patent-infringement damages...
